Cargando…

PD-L1 expression in small cell lung cancer: should we designate it for assignment?

Detalles Bibliográficos
Autor principal:	Hakozaki, Taiki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512465/ https://www.ncbi.nlm.nih.gov/pubmed/34733619 http://dx.doi.org/10.21037/tlcr-21-720

Ejemplares similares

Quantitative spatial profiling of PD-1/PD-L1 interaction in patients with cancer
por: Hakozaki, Taiki
Publicado: (2023)

Re-administration of immune checkpoint inhibitors for patients with non-small cell lung cancer
por: Hakozaki, Taiki
Publicado: (2022)

Immune checkpoint inhibitors for patients with gene-rearranged non-small cell lung cancer
por: Uehara, Yuji, et al.
Publicado: (2022)

Efficacy of second-line chemotherapy after immunotherapy in advanced non-small cell lung cancer
por: Hirata, Tsuyoshi, et al.
Publicado: (2023)

Switching administration of anti‐PD‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series and literature review
por: Kitagawa, Shingo, et al.
Publicado: (2020)

PD‐1/PD‐L1 co‐location: A novel biomarker for immunotherapy response in non‐small cell lung cancer
por: Diao, Xiayao, et al.
Publicado: (2022)

Should we close small ventricular septal defects?
por: Viswanathan, Sangeetha, et al.
Publicado: (2017)

(18)F-FDG PET/CT to predict tumor PD-L1 expression and response to PD-(L)1 blockade in patients with non-small-cell lung cancer
por: Borm, Frank Johannes, et al.
Publicado: (2020)

How Should We Assign Large Infiltrative Hepatocellular Carcinomas for Staging?
por: Lee, Yoo Jin, et al.
Publicado: (2020)

On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer
por: Correale, Pierpaolo, et al.
Publicado: (2020)

Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2022)

PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer
por: Larsen, Trine Vilsbøll, et al.
Publicado: (2019)

Brain-lung crosstalk: how should we manage the breathing brain?
por: Wahlster, Sarah, et al.
Publicado: (2023)

DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
por: Zhu, Zhongling, et al.
Publicado: (2018)

Should We Be Permissive with Hypercapnia?
por: Nassar, Boulos
Publicado: (2022)

What Should We Eat?
Publicado: (1909)

Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients
por: Arrieta, Oscar, et al.
Publicado: (2017)

PD-L1 expression testing in non-small cell lung cancer
por: Teixidó, Cristina, et al.
Publicado: (2018)

Design of PD-L1 inhibitors for lung cancer
por: Udhwani, Trishang, et al.
Publicado: (2019)

Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report
por: Hakozaki, Taiki, et al.
Publicado: (2018)

Should we keep on doing robotic surgery to treat lung cancer in 2020?
por: Montagne, François, et al.
Publicado: (2020)

How we should tailor the nodal staging for various types of lung cancer?
por: Watanabe, Shun-ichi
Publicado: (2020)

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
por: D'Incecco, A, et al.
Publicado: (2015)

The ‘novel’ influenza A(H1N1) enigma: is it a pandemic, how should we respond, what should we call it?
por: Hampson, Alan W.
Publicado: (2009)

The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung adenocarcinomas?
por: BULUTAY, Pınar, et al.
Publicado: (2021)

Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade
por: Kroemer, Guido, et al.
Publicado: (2021)

Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma
por: Hakozaki, Taiki, et al.
Publicado: (2020)

A RESPONSIBILITY THAT WE SHOULD NOT SHIRK
por: Kuruvilla, K.
Publicado: (1995)

Should we SUSPEND MET? Not really
por: Sairam, Krishnamurthy
Publicado: (2016)

Should we hunt a metric?
por: Villar, Richard (Ricky)
Publicado: (2019)

Why should we continue to learn?
por: Golnik, Karl
Publicado: (2017)

Should we open the reviewing process
por: Mrša, Vladimir
Publicado: (2021)

CUREs in biochemistry—where we are and where we should go
por: Bell, Jessica K., et al.
Publicado: (2016)

PD-L1 expression is associated with advanced non-small cell lung cancer
por: Chen, Zhiquan, et al.
Publicado: (2016)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Respondent driven sampling—where we are and where should we be going?
por: White, Richard G, et al.
Publicado: (2012)

Should we, can we, halt the rise in prescribing for pain and distress?
por: Byng, Richard
Publicado: (2020)

COVID-19 Vaccination. Where Are We and Where Should We Go?
por: Peña-Otero, David
Publicado: (2022)

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
por: Hirsch, Laure, et al.
Publicado: (2018)

Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?
por: Mienko, Fiona, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kddbuu5s42dl1bqgnfreskca5i